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Abstract 
 Vibrio vulnificus, a gram-negative bacterium, is the leading cause of 
seafood-borne illnesses and mortality in the United States.  Previous studies of 
bacterial pathogens have identified a metabolite essential to V. vulnificus growth 
and function.  1-deoxy-D-xylulose 5-phosphate reductoisomerase (Dxr) is an 
essential enzyme in the viability of many bacteria and catalyzes the rearrangement 
of 1-deoxy-D-xylulose 5-phosphate (Dxp) to 2-C-methylerythritol 4-phosphate 
(MEP) within the MEP pathway found in plants and bacteria.  Previous studies 
have been conducted to characterize Dxr homologs from other pathogens 
including E. coli, M. tuberculosis, and P. falciparum.  Information on the structural 
and enzymatic characteristics of Dxr from Vibrio vulnificus, or VvDxr, is not known.  
In this study, we show for the first time apo and ligand-bound structures of VvDxr.  
The structures are from both His-tag cleaved (cut) and uncleaved (uncut) protein.  
Using Dxr homologs, we identify similarities in the structural characteristics among 
these enzymes.  The binding characteristics were also studied to identify parallels 
between the enzyme’s affinity for metals and inhibitors.  Our findings will provide 
basis for design of Dxr inhibitors that may find application as antimicrobial 
compounds.   
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Chapter 1 
Introduction 
 Vibrio vulnificus is a gram- negative bacterium viable in warm, brackish, 
coastal water.  This particular species of Vibrio gains access to the body by 
ingestion of contaminated raw seafood or through absorption into an open wound 
that has been in vulnificus contaminated water [1-3].  Immunocompromised 
individuals are more susceptible to V. vulnificus infections, and the resulting 
symptoms are more severe in comparison to healthy individuals [3-4].  V. vulnificus 
is the leading cause of seafood-borne mortality in the United States with fatalities 
of over sixty percent due to primary septicemia and over twenty percent resulting 
from open wound contamination [1-5].  To avoid severe infection and fatality, 
immediate diagnosis and treatment is urged.   
Previous studies have identified an enzymatic pathway, ubiquitous in most bacteria 
and bacteria (Fig 1.1) [6-7].  The non-mevalonate or MEP pathway produces the 
isoprenoids, isopentenyl diphosphate (IPP) and dimethylallyl pyrophosphate 
(DMAPP).  These compounds are essential precursors to the biosynthesis of 
steroids necessary for vital functions within the bacterial cell, including metabolism 
functions and cell wall generation [8].  Because this pathway is absent in 
mammals, it is an ideal target for drug studies.  Dxr catalyzes the reduction and 
isomerization of 1-deoxy-D-xylulose 5-phosphate (Dxp) to 2-C-methylerythritol 4- 
phosphate (MEP). This reaction is the committed step in the pathway, and NADPH 
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and divalent cation are cofactors.  A study seeking to identify essential metabolites 
in this species of Vibrio indicated that knocking down the gene encoding for Dxr 
rendered the bacteria nonviable [6].  A vast amount of other infections is caused 
by pathogenic bacteria that also utilize the MEP pathway, including pneumonia, 
cholera, and gonorrhea [8].  Inhibition of the critical Dxr enzyme can lead to 
eradication of Vibrio vulnificus and a host of other pathogens. 
Presently, fosmidomycin and FR-900098, current antimalarial agents, have 
been very effective in inhibiting the activity of Dxr.  Previous studies have also 
identified a different class of antibiotics, bisphosphonates, which are also capable 
of inhibiting the activity of this enzyme [9-11].  Another Dxr inhibitor that has gained 
interest is 2,6 Pyridinedicarboxylic acid (2,6 PDC) derivative [12].  As Vibrio 
vulnificus infections have increased in the past few years, details on the VvDxr 
enzyme and how it interacts with this compound can provide insight into the 
development of a new class of PDC-based inhibitors.  
The structure of Dxr has been determined via crystallography and studied 
in organisms including Escherichia coli (EcDxr), Mycobacterium tuberculosis 
(MtDxr), and Plasmodium falciparum (PfDxr).  The enzyme crystallizes as a 
homodimer, and each subunit consists of two domains: a catalytic domain and a 
C-terminal domain [13-15].  The residues making up the active site are highly 
conserved.  Although the structures of other Dxr homologs have been determined, 
there has been no structure determined for the VvDxr enzyme until now.   
We are interested in the isolation and structural determination of VvDxr.  We 
show both the apo and ligand-bound protein structures of VvDxrprotein, either with 
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the polyhistidine tag uncleaved (uncut) or cleaved (cut).  Details of the polyhistidine 
tag and its removal can be found in the Material and Methods section.  We alsos 
provide information of their similarities to the previously studied homologs.  In this 
study, we show that VvDxr shares similar structural characteristics to other 
homologs.  Additionally, we show that metal cofactors promote thermal stability of 
the VvDxr protein.   
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Figure 1.1.  Non-mevalonate or MEP pathway.  This pathway is found in most 
plants and bacteria and is named for 2-C-methyl-D-erythrito 4-phosphate (MEP) 
[7] 
  
2-C-methylerythritol-4-phosphate
(MEP)
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Chapter 2 
Results and Discussion 
 
OVEREXPRESSION AND PURIFICATION OF VVDXR 
  VvDxr was overexpressed with the initial isolation yielding approximately 
150 mg of the protein per 1 L of culture.  Protein purity was confirmed using SDS-
Page gel (Fig 2.1) and mass spectrometry (Fig 2.2).  The protein was further 
purified by gel filtration.  The resulting elution profile contained one sharp peak 
corresponding to the  molecular weightof a VvDxr dimer (~88 kDa).  Cleavage of 
the protein’s polyhistidine tag was successful, and the cut VvDxr was verified after 
SDS-Page gel identification prior to additional purification by gel filtration.  (Fig 2.3).  
These results indicate that VvDxr is a dimer in solution. 
VVDXR CRYSTALLIZATION  
All crystallization experiments were conducted at 293 K.  VvDxr crystals 
were identified within 48 hours using protein from the initial purification of VvDxr.  
Crystals were identified in a variety of conditions including Wizard Classic 1 
(Rigaku, Bainbridge Island, WA) conditions 9, 28, 34, 41, and 47, and Wizard 
Classic 2 (Rigaku, Bainbridge Island, WA) conditions 10, 29, 33, 37, 46, and 48 
(Table 1).   
The aforementioned conditions were remade in our lab, and crystallization 
drops were set using the hanging drop vapor diffusion method.  Crystals identified 
from the optimized screens were Wizard Classic 2 conditions 33 and 
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37.  These screens were further optimized by small increments to produce the 
conditions found in Tables 2 and 3.  From the optimized conditions, crystals were 
formed, and we were later able to determine the first structure of VvDxr (Fig. 2.4).    
2.1 VVDXR SEQUENCE ANALYSIS 
 VvDxr contains 402 residues in each chain of the homodimeric structure.  
The sequence of VvDxr was aligned with previously determined Dxr homologs.  
The percent identity is listed in the legend of Figure 2.5.  Sequence conservation 
was mapped on to VvDxr structure using EcDxr and ligands present in the active 
site in order to compare the active site of this protein with homologs.  Figure 2.6 
shows sequence conservation mapped on VvDxr structure [22-23]. The analysis 
of the sequence conservation reveals that the highly conserved residues cluster 
near of both the active site and flexible loop.   
 
2.2 STRUCTURAL ANALYSIS 
 The first diffraction data were obtained from a VvDxr crystal grown from an 
optimized condtion: 0.1 M Sodium citrate pH 5.0, 1.2 M Ammonium phosphate and 
0.2 M NaCl.  The native crystal was formed from uncut protein.  The crystal formed 
had C2221 symmetry and a dimeric assembly in the asymmetric unit.  Further 
analysis of the crystal structure revealed a clearly distinguishable N-terminal and 
C-terminal domain, along with a highly conserved binding domain or active site.   
 Subsequent diffraction data were obtained from crystals grown in the 
following conditions: (1) 0.1 M Sodium citrate pH 5.0, 0.8 M Ammonium phosphate, 
0.2 M Sodium chloride and (2) 0.1 M Sodium citrate pH 5.5, 0.8 M Ammonium 
phosphate, 0.2 M Sodium chloride.  Crystals formed in conditions (1) and (2) were 
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allowed to form before soaking the crystals in conditions that only differed in the 
progressively decreasing phosphate Ammonium phosphate concentrations (0.8 M, 
0.6 M, 0.4 M, 0.2 M, 0 M Ammonium phosphate).  Solid manganese (II) chloride 
and 2 mM fosmidomycin (condition 1) and 2 mM FR900098 (condition 2) were 
added to the cryo-protectant drop.   
Further crystallization experiments continued utilizing Index screen 
(Hampton Resarch, Aiso Viejo Dimensions/Rigaku CA) and the sitting drop vapor 
diffusion method.  Despite the success of the hanging drop experiments, crystals 
were formed, but not in the same time frame as before.  The crystals produced in 
1.0 M Succinic acid pH 7.0, 0.1 M HEPES pH 7.0, 1% w/v PEG 2000 were free of 
phosphate and sulfate and diffracted.  These conditions were further optimized, 
and drops were set using the sitting drop vapor diffusion method.  Despite the 
various conditions, all crystal structures had C2221 symmetry and a dimeric 
assembly in the asymmetric unit.  Tables 2.4 and 2.5 outline the data collection 
and processing details for all deposited structures.  Tables 2.6 and 2.7 detail the 
refinement statistics for these structures.   
 
2.3 VVDXR OVERALL ANALYSIS 
 The first structure to be determined was native uncut VvDxr.  All VvDxr 
structures determined thereafter used this structure as a model.  The VvDxr apo- 
structure was determined at 2.35 Å resolution.  VvDxr crystallized as a homodimer 
with each monomer containing a phosphate ion in the same position in active site, 
and the flexible loops in both monomers are ordered.  This model of VvDxr was 
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deposited to the PDB with accession code 5KQO. Two structures were determined 
after working to ‘soak out’ the phosphate and co-crystallize with fosmidomycin or 
FR900098.  In both structures, the VvDxr protein crystallized as a homodimer.  
Although the protein did not crystallize with neither fosmidomycin nor FR900098, 
manganese ions in are present in both active sites instead of phosphate.  VvDxr 
in the presence of FR900098 has an ordered flexible loop for chain B, but not for 
chain A. We assume this to be due to the negative cooperativity of the Dxr enzyme 
[16].  These His-tag cleaved structures were deposited to the PDB with accession 
codes, 5SK1 and 5KRR, respectively, and determined at 2.4 Å and 2.5 Å 
resolutions.   
 After successfully crystallizing VvDxr in the absence of phosphate and 
sulfate, we were able to determine a structure of cut VvDxr protein.  The protein 
was crystallized in the absence of ligands.  The electron density around the flexible 
loop in chain A is disordered.  Molecular replacement was performed using 5KQO 
as a model.  The structure was determined at 2.2 Å and deposited to the PDB with 
accession code 5KRY.   
2.4 ACTIVE SITE 
The first structure of VvDxr contained a phosphate in the active site.  The 
structure of Dxr contained a phosphate ion in the active site.  Superposition of 
VvDxr with PfDxr in complex with FR900098 (PDB code: 3AUA) showed the 
phosphate ions to be located in the active site.  Figure 2. 7 shows that the ions are 
located in the same position in the homologs. The residues making up the highly 
conserved active site were: G11, S12, I13, G14, K37, N38, A123, L122, A123, 
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N124, K125, E126, D150, S151, E152 and H153.  There is also a highly conserved 
flexible loop made up by residues H209, P210, N211, W212 (Fig 2.8).   
After multiple structures have been determined with phosphate in the active 
site, we continued to soak the protein in either NADPH, FR900098 or 
fosmidomycin in anticipation that the inhibitors will co-crystallize with the protein.  
This discovery led us to focus on crystallizing VvDxr in the previously mentioned 
condition and then remove the phosphate and sulfate by soaking them out of the 
crystal.  Another method we tried was to crystallize VvDxr in conditions containing 
no phosphate or sulfate. We were able to determine two structures after using this 
soaking out technique.  However, the inhibitors did not crystallize with the protein.  
Instead, the divalent cation was crystallized in the active site.   
 
2.5 VVDXR IN COMPLEX WITH METALS 
 
 Previous structures of Dxr homologs deposited in the PDB are in complex 
with either NADPH, a divalent cation, a previously studied Dxr inhibitor or a 
combination of these [10][15-16].  Our study sought to determine the crystal 
structure of VvDxr in complex with cofactors and/or metals.  Although efforts to co-
crystallize the protein with inhibitors and/or NADPH cofactor was unsuccessful, we 
were able to determine the structures of multiple VvDxr structures in complex with 
metal cations.   
 Crystals were also grown in the presence of 0.8 M Succinic acid.  Diffraction 
data was collected and a structure was determined.  In the active site, there was 
a magnesium ion in the active site.  To quantify the amount of magnesium present 
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in the active site, our sample was tested using Inductively Coupled Plasma-Mass 
Spectrometry.  This form of mass spectrometry is used to detect and analyze the 
metals present in a sample.  The results of the experiment performed by Dr. Lijian 
He (Mass Spectrometry Manager, University of South Carolina) suggested there 
is approximately 0.5 mole of magnesium ion per chain in our VvDxr structure.  
These results correspond to the density present in the active sites of our structure.   
DIFFERENTIAL SCANNING FLUORIMETRY 
 VvDxr stability was measured using Differential Scanning Fluorimetry 
(DSF).  Soluble VvDxr protein is incubated with Sypro-orange, a fluorescent probe.  
As the protein is heated, the hydrophobic residues are exposed, and the probe 
binds to the exposed residues.  The temperature at which the protein fluoresces 
denotes the melting temperature and thermal stability of the protein [22].  In our 
experiment, we wanted to determine the thermal stability of native VvDxr and then 
measure which ligands may promote an increase in thermal stability.  By identifying 
an increase in the melting temperature of VvDxr in the presence of ligand, we 
assumed the ligand binds to our protein.  
The cut VvDxr is slightly more stable than uncut VvDxr (Fig 2.9).  VvDxr 
remained more stable in the presence of divalent cations, in particular manganese 
(II) chloride, magnesium (II) chloride, and calcium (II) chloride (Fig 2.10).  The 
thermal stability of the protein was also tested in the presence of NADPH and 
manganese (II) chloride (Fig 2.11).  The VvDxr melting temperature increased, 
confirming our hypothesis that VvDxr is more stable in the presence of NADPH 
and magnesium.   
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 To identify other ligands that may promote thermal stability of the VvDxr 
protein, the experiment was carried out in the presence of 386 different ligands.  
Initially, our aim was to also study the thermal stability of VvDxr with its’ substrate, 
1-deoxy-D-xylulose 5 phosphate, or Dxp.  However, Dxp is too costly to purchase 
or synthesize.  Figures 2.12-14 provides the results. Divalent cations were among 
the compounds to promote thermal stability.  After identifying compounds 
promoting thermal stability, crystallization experiments were carried using various 
phosphate free screens and all of the ligands from the DSF screen and the sitting 
drop vapor diffusion method.  Our purpose was to co-crystallize VvDxr in complex 
with the ligands shown to increase the protein’s melting temperature and identify 
inhibitors or homologues Dxp.  Contrary to our results, we were able to determine 
a structure of VvDxr in complex with arginine, a compound that did not improve 
thermal stability.  The crystal was grown in 0.8 M Sodium potassium tartrate, 20% 
PEG 3350, 5 mM Arginine, solved at 2.3 Å and deposited to the PDB with the 
accession code of 5KRV.  Interestingly, the arginine is not found anywhere near 
the active site (Fig. 2.15).   
 
ISOTHERMAL TITRATION CALORIMETRY 
 After identifying metals that co-crystallize or promote thermal stability of 
VvDxr, Isothermal Titration Calorimetry (ITC) was performed to study the binding 
thermodynamics.  From the results, we are able to calculate: number of active sites 
(N), dissociation constant (K), change in enthalpy (ΔH), change in entropy (ΔS), 
and Gibbs free energy (ΔG) values.  The results are consistent with ITC studies 
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from Dxr homologs [16-17].  VvDxr was first tested with either manganese (II) 
chloride or magnesium (II) chloride in the buffer solution.  NADPH was injected into 
the protein solution, and the resulting isotherm is show in Figure 2.16.  The results 
affirm our hypothesis: the binding of VvDxr to NADPH is exothermic.  The 
thermodynamic parameters observed are similar to those of other Dxr homologs.  
NADH binding was also tested to prove that NADH does not bind to VvDxr.  The 
results indicated that no binding occurred.   
 ITC was also used to determine if there was any indication of binding of 
ligands or potential inhibitors binding to VvDxr.  The compounds shown to promote 
VvDxr thermal stability were first run with buffer only to ensure there was no ligand-
ligand binding. Afterwards, ligands were run with protein.  Using 2,6 
Pyridinedicarboxylic acid as the ligand, the thermodynamics of binding was 
measured (Fig. 2.17).  There is indication of the ligand-protein binding.  Further 
studies are necessary to determine if 2,6 PDC binds in the active site of the protein.   
CONCLUSION AND FUTURE DIRECTIONS 
 The crystal structures of VvDxr were all solved in the same space 
group, and without ligands bound in the active site.  This happens in the presence 
or absence of phosphate, sulfate, or metals.  It is possible that the protein prefers 
a certain crystallization form and thereby prevents the binding of ligands.  Co-
crystallization studies should continue to incorporate the cofactor(s) and/or 
inhibitors in the active site.  Current enzymatic studies of 1-deoxy-D-xylulose-5-
phosphate synthase (Dxs) to produce DXP for enzymatic assays involving Dxr 
have been inconclusive, but further analysis can provide more insight into the 
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characteristics of this protein. . Although there is indication of 2,6 PDC binding to 
our protein, additional studies with this and other ligands may lead to the design of 
a new class of inhibitors.   
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TABLE 2.1. Wizard crystallization conditions. 
Crystallization conditions for VvDxr crystals identified after initial screening 
Screen Condition 
# 
Condition contents 
Wizard Classic 
1 
9 1000 mM Ammonium phosphate dibasic, 100 mM 
Sodium acetate/Acetic acid pH 4.5 
 28 20% (w/v) PEG 
 34 10 % (w/v) PEG 8000, 100 mM 
Imidazole/Hydrochloric acid pH 8.0 
 41 2000 mM Ammonium sulfate, 100 mM Tris 
base/hydrochloric acid pH 7.0, 200 mM Lithium 
sulfate 
 47 2500 mM Sodium chloride, 100 mM 
imidazole/Hydrochloric acid pH 8.0, 200 mM Zinc 
acetate 
Wizard Classic 
2 
10 1000 mM Ammonium phosphate dibasic, 100 mM 
Tris base/Hydrochloric acid pH 8.5 
 29 1260 mM Ammonium sulfate, 100 mM 
CHES/Sodium hydroxide pH 9.5, 00 mM Sodium 
chloride 
 33 1000 mM Ammonium phosphate dibasic, 100 mM 
Sodium citrate tribasic/Citric acid pH 5.5, 200 mM 
Sodium chloride 
 37 1000 mM Potassium sodium tartrate, 100 mM Tris 
base/Hydrochloric acid pH 7.0, 200 mM Lithium 
sulfate 
 46 1000 mM Ammonium phosphate dibasic, 100 mM 
imidazole/Hydrochloric acid pH 8.0, 200 mM 
Sodium chloride 
 48 1000 mM Potassium sodium tartrate, 100 mM 
MES/Sodium hydroxide pH 6.0 
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TABLE 2.2.  Optimized Wizard 2 condition 33.  
Original condition: 0.1 M Sodium citrate pH 5.5, 1 M Ammonium phosphate 
dibasic, 0.2 M Sodium chloride  
pH Condition contents 
5.0 
0.1 M Sodium 
citrate 
0.2 M Sodium 
chloride 
0.5 M Ammonium phosphate 
0.8 M Ammonium phosphate 
1.2 M Ammonium phosphate 
1.4 M Ammonium phosphate 
1.6 M Ammonium phosphate 
5.5 
0.1 M Sodium 
citrate 
0.2 M Sodium 
chloride 
0.5 M Ammonium phosphate 
0.8 M Ammonium phosphate 
1.2 M Ammonium phosphate 
1.4 M Ammonium phosphate 
1.6 M Ammonium phosphate 
6.0 
0.1 M Sodium 
citrate 
0.2 M Sodium 
chloride 
0.5 M Ammonium phosphate 
0.8 M Ammonium phosphate 
1.2 M Ammonium phosphate 
1.4 M Ammonium phosphate 
1.6 M Ammonium phosphate 
5.0 0.1 M Sodium 
citrate 
0.2 M Sodium 
chloride 
1.0 M Ammonium phosphate 
6.0 
5.5 
0.1 M Sodium 
citrate 
0.1 M Sodium 
chloride 
1.0 M Ammonium phosphate 
0.150 M Sodium 
chloride 
0.250 M Sodium 
chloride 
0.300 M Sodium 
chloride 
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Table 2.3. Optimized Wizard 2 condition 37 
Original condition: 0.1 M Tris pH 7.0, 1 M Potassium sodium tartrate, 0.2 M 
Lithium sulfate 
pH Condition contents 
7.0 0.1 M Tris 
0.5 M Potassium sodium tartrate 
0.2 M Lithium 
sulfate 
0.8 M Potassium sodium tartrate  
1.2 M Potassium sodium tartrate 
1.4 M Potassium sodium tartrate 
1.6 M Potassium sodium tartrate 
7.5 0.1 M Tris 
0.5 M Potassium sodium tartrate 
0.2 M Lithium 
sulfate 
0.8 M Potassium sodium tartrate  
1.2 M Potassium sodium tartrate 
1.4 M Potassium sodium tartrate 
1.6 M Potassium sodium tartrate 
8.0 0.1 M Tris 
0.5 M Potassium sodium tartrate 
0.2 M Lithium 
sulfate 
0.8 M Potassium sodium tartrate  
1.2 M Potassium sodium tartrate 
1.4 M Potassium sodium tartrate 
1.6 M Potassium sodium tartrate 
7.5 
0.1 M Tris 1.0 M Potassium sodium tartrate 
0.2 M Lithium 
sulfate 8.0 
7.0 0.1 M Tris 1.0 M Potassium sodium tartrate 
0.1 M Lithium 
sulfate 
0.150 M Lithium 
sulfate 
0.250 M Lithium 
sulfate 
0.3 M Lithium 
sulfate 
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TABLE 2.4.  Summary of VvDxr (native and metal-bound) data collection  
The table summarizes native VvDxr and cut VvDxr structures in complex with 
Mn2+ data collection and processing. The numbers in parenthesis refer to the 
highest resolution shell. 
PDB Accession code 5KQO 5KS1 5KRR 
Diffraction source APS (22BM) APS (19ID) APS (19ID) 
Wavelength (Å) 1.000 0.979 0.979 
Detector Marmosaic 225 
mm CCD 
ADSC Q315r ADSC Q315r 
Space group C2221 C2221 C2221 
a, b, c (Å) 65.5 148.9 244.1 64.1 149.3 243.8 64.8 149.1 
242.5 
Resolution range (Å) 50.0-2.35 (2.39-
2.35) 
50.0-2.40 (2.44-
2.40) 
50.0-2.50 (2.54-
2.50) 
σ Cutoff -3 σ -3 σ -3 σ 
Total No. of 
reflections 
49916 (2482) 46042 (2108) 38225 (1840) 
Completeness (%) 99.9 (100.0) 99.2 (92.4) 93.4 (91.3) 
Redundancy 4.5 (4.6) 5.6 (5.0) 5.3 (5.4) 
I/σ(I) 33.2 (4.7) 31.0 (2.7) 16.9 (2.9) 
Rr.i.m. 0.067 0.068 0.088 
Rp.i.m. 0.031 0.028 0.037 
Overall B factor from 
Wilson plot (Å2) 
46.8 52.3 33.1 
CC ½ 0.948 0.934 0.917 
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Table 2.5: Summary of VvDxr in complex with Arginine and cut VvDxr 
PDB Accession code 5KRV 5KRY 
Diffraction source 22ID 22BM 
Wavelength (Å) 1.000 1.000 
Detector Rayonix MX 300-HS Marmosaic 225 mm 
CCD 
Space group C2221 C2221 
a, b, c (Å) 49.8  93.0  128.4 49.5  92.1  128.6 
Resolution range (Å) 50.0-2.30 (2.34-2.30) 50.0-2.30 (2.34-2.30) 
σ Cutoff -3 σ -3 σ 
Total No. of reflections 53084 (2578) 53399 (2621) 
Completeness (%) 99.9 (99.8) 99.5 (98.2) 
Redundancy 7. (7.5) 8.1 (7.4) 
I/σ(I) 22.7 (1.6) 21(2.1) 
Rr.i.m. 0.100 0.118 
Rp.i.m. 0.038 0.037 
Overall B factor from 
Wilson plot (Å2) 
51.3 49. 587 
CC ½ 0.859 0.859 
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Table 2.6: Summary of 5KQO, 5KRV, AND 5KRY refinement statistics  
PDB Accession 
Code 
5KQO 5KRV 5KRY 
Resolution range 
(Å) 
50-2.35 (37.23-
2.35) 
500-2.30 
(28.34-2.30) 
50.0-2.30 (35.84-
2.30) 
Completeness (%) 99.7 (99.50) 99.4 (99.5) 99.9 (99.9) 
σ Cutoff  0 0 
No. of reflections, 
working set 
47370  50748 
No. of reflections, 
test set 
2455 2686 2571 
Final Rcryst 0.232(0.185)  0.184 (0.186) 
Final Rfree 0.182 (0.210)  0.225 (0.216) 
No. of non-H 
atoms 
6209 6155 6343 
Protein 5971 5913 5957 
Ligand 35 67 16 
Solvent 203 175 370 
R.m.s. deviations 
Bonds (Å) 0.70 0.55 0.80 
Angles (º) 0.82 0.74 0.85 
Average B factors (Å2) 
Protein 53 63 46 
Ligand 55 65 55 
Ramachandran plot 
Most favored (%) 98 99 99 
Allowed (%) 2 1 1 
Visible Residues 
Chain A 1-398 1-394 1-191, 193, 195-
207, 209-348, 
30-375, 377-400 
Chain B 1-397 1-393 1-149, 151-195, 
197-208, 210-
229, 231-375, 
377-397, 399-
400 
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Table 2.7: Summary of 5KS1 AND 5KRR refinement statistics  
PDB Code 5KS1 5KRR 
Resolution range (Å) 50.0-2.40(29.8-2.39) 50.0-2.5 (37.58-2.50) 
Completeness (%) 99.2 (98.9) 84.1 (84.1) 
σ Cutoff 0 0 
No. of reflections, 
working set 
43578 1840 
Final Rcryst 0.189 0.191 (0.192) 
Final Rfree 0.191 0.227 (0.230) 
No. of non-H atoms 6094 6150 
Protein 5900 5918 
Ligand 36 23 
Solvent 158 209 
R.m.s. deviations 
Bonds (Å) 0.97 0.80 
Angles (º) 0.97 0.87 
Average B factors (Å2) 
Protein 82 39 
Ligand 98 56 
Ramachandran plot 
Most favored (%) 98 98 
Allowed (%) 2 2 
Visible Residues 
Chain A 1-118, 120-242, 245-327 1-195, 197/198, 202-
346, 348, 350-351, 354-
367, 367-374, 378-377-
382, 384-397, 399-400, 
402-405 
Chain B 1-118, 120-25, 29-309, 
311-327 
1-195, 197-367, 369-
375, 377-397, 399-400, 
402-405 
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Figure 2.1: VvDxr gel electrophoresis.  These results are typical of thepurification 
of VvDxr.  The bands correspond to the expected molecular weight of the protein.  
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Figure 2.2.  Mass spectrometry of uncut and cut VvDxr.  The molecular weights 
shown correspond to the expected molecular weight of both the cut and uncut 
forms.   
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Figure 2.3 Chromatogram of cut VvDxr.  The strong sharp peak reaching 
approximately 240 mAU also shows the protein is pure and present in abundant 
quantities.  In comparing this elution profile to that of uncut VvDxr, there is a slight 
shift in where the protein elutes from the column. 
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Figure 2.4. VvDxr monomer.  The cartoon structure of VvDxr is depicted above.  
A phosphate ion is shown in the active site.   
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Figure 2.5. Multiple sequence alignment of Dxr homologs.  This alignment was 
obtained from Kalign [20] to show Dxr enzymes from M. tuberculosis, E. coli, P. 
falciparum, and V. vulnificus.  The percent identity when compared to V. vulnificus 
is 41% for M. tuberculosis, 62% for E. coli, and 37% for P. falciparum.  
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Figure 2.6:  Conserved VvDxr residues.  Above is a cartoon depiction showing the 
conserved residues of VvDxr mapped on protein structure [22-23]. E. coli Dxr (PDB 
ID: 2EGH)  structure was used to show fosmidomycin and NADPH binding sites. 
Fosmidomycin and NADPH are shown as orange sticks.  The highly conserved 
residues are located towards the active site and become more variable as it moves 
toward the surface of the enzyme [16].  
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Figure 2.7 Juxtaposition of Dxr active sites. Left: PfDxr in complex with FR900098 
(PDB code: 3AUA).  Right: VvDxr with phosphate ion.  The phosphate groups are 
in the same position in both structures.    
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Figure 2.8. Flexible loop of VvDxr.  The VvDxr monomer determined in our lab is 
shown with the flexible loop colored in green.  The flexible loop moves over the 
active site upon ligand binding. Ussin et al., in preparation 
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NaCl 
(M) 
0 50 54 56 54 56 54 54 52 50 44 32 40     
0.125 50 54 56 54 56 54 54 52 50 50 46 32 cut 
VvDxr 
0.25 50 54 58 56 56 56 54 52 52 50 48 32 
0.5 52 54 58 56 56 56 52 52 50 50 48 44     
0.625 50 56 58 56 56 56 54 52 50 50 48 44     
0.75 50 56 58 56 56 56 56 54 50 52 50 46     
0.875 50 56 58 58 58 58 56 54 52 52 50 50     
1 54 58 62 62 64 62 62 60 60 58 56 54     
                                
NaCl 
(M) 
0 48 52 54 52 52 50 50 48 32 40 30 30     
0.125 48 52 54 52 52 52 50 48 44 32 32 30 uncut 
VvDxr 
0.25 46 50 54 52 52 52 50 48 46 32 32 30 
0.5 46 50 54 54 54 52 50 48 46 44 32 30     
0.625 60 50 54 54 54 52 50 48 46 46 32 30     
0.75 46 50 54 54 54 52 50 48 46 46 32 32     
0.875 46 52 50 54 54 54 54 52 50 48 46 44     
1 48 52 58 58 60 60 60 58 56 52 50 48     
 
Figure 2.9 Thermal stability: uncut vs cut VvDxr.  The melting temperatures of the 
cut VvDxr are slightly higher indicating an increase in the thermal stability.   
 
  
30 
 
 
 
Figure 2.10 Thermal stability: uncut VvDxr in presence of metals.  The melting 
temperature of VvDxr increased in the presence of divalent cations, in particular 
manganese (II) chloride and magnesium (II) chloride.  Copper (II) chloride caused 
VvDxr stability to immediately decrease. The 90° temperatures are due to 
experimental errors.     
  
0 48 54 56 54 56 54 54 30 30 30 30 30
0.125 48 52 56 54 56 54 30 30 30 30 30 30
0.25 46 52 56 54 56 56 54 30 30 30 30 30
0.5 30 50 56 54 56 56 54 30 30 30 30 30
0.625 30 30 56 56 56 56 54 30 30 30 30 30
0.75 44 50 56 56 58 56 54 30 30 30 30 30
0.875 46 30 56 56 58 58 56 30 30 30 30 30
1 30 30 58 58 60 60 60 58 58 30 30 30
0 48 52 54 52 52 50 50 48 44 30 30 30
0.125 48 50 52 52 52 52 50 48 44 32 32 30
0.25 46 50 54 52 52 52 50 48 46 32 32 40
0.5 46 50 54 54 52 52 50 48 46 32 32 40
0.625 46 50 54 54 54 52 52 48 46 46 32 40
0.75 46 50 54 54 54 54 52 50 48 46 32 32
0.875 46 50 54 54 54 52 54 50 50 48 46 44
1 46 52 58 58 50 58 60 58 54 52 48 52
0 30 30 30 30 30 30 30 30 30 30 30 30
0.125 30 30 30 30 30 30 30 30 30 30 30 30
0.25 30 30 30 30 30 30 30 30 30 30 30 30
0.5 30 30 30 30 30 30 30 30 30 30 30 30
0.625 30 30 30 30 30 30 30 30 30 30 30 30
0.75 30 30 30 30 30 30 30 30 30 30 30 30
0.875 30 30 30 30 30 30 30 30 30 30 30 30
1 30 30 30 30 30 30 30 30 30 30 30 30
0 48 52 54 52 50 50 50 48 46 32 32 30
0.125 46 50 52 52 52 52 50 50 46 44 32 32
0.25 46 50 54 52 52 52 52 50 48 32 32 32
0.5 46 50 52 52 52 52 52 50 48 46 32 32
0.625 46 50 54 52 52 52 52 50 50 48 44 32
0.75 46 50 54 54 54 52 52 50 50 48 44 32
0.875 44 50 54 54 54 52 54 52 52 50 48 46
1 48 52 58 58 52 58 60 58 58 54 50 50
NaCl (M) 0 48 52 54 52 54 56 58 58 56 50 30 32
0.125 48 52 54 54 56 58 56 58 56 56 52 48
0.25 46 50 54 54 56 58 58 58 58 56 90 90
0.5 46 50 54 54 56 58 58 58 58 56 90 90
0.625 46 50 54 54 58 58 60 60 58 56 90 90
0.75 46 52 54 54 58 60 58 60 58 58 90 90
0.875 46 50 56 56 60 60 62 62 60 58 90 90
1 46 52 58 60 64 66 66 66 64 60 90 90
NaCl (M) Vv1 uncut 2 mM 
Copper  (II) chloride
NaCl (M)
NaCl (M)
NaCl (M)
uncut VvDxr 2 mM 
Manganese (II) 
chloride
Vv1_uncut with 2 
mM Calcium (II) 
chloride
Vv1_uncut with 2 
mM Zinc (II) chloride
Vv1_uncut with 2 
mM Magnesium 
chloride
31 
 
 
 
Figure 2.11 Thermal stability: uncut VvDxr in presence of NADPH and metals.  
VvDxr yielded higher melting temperatures when in the presence of both NADPH 
cofactor and either manganese (II) chloride or magnesium (II) chloride.    
  
NaCl (M) 0 50 54 56 56 56 52 50 48 46 50 48 52
0.125 48 52 56 56 54 52 50 48 46 50 48 46
0.25 46 52 54 54 54 52 50 48 46 50 48 46
0.5 46 52 54 54 54 52 50 48 48 52 48 48
0.625 44 50 54 54 54 52 50 48 48 50 50 48
0.75 44 50 54 54 54 52 50 50 48 50 50 48
0.875 44 50 54 56 54 54 52 50 50 52 50 50
1 44 52 56 58 58 58 56 56 54 54 54 54
NaCl (M) 0 50 54 56 56 60 62 56 62 62 62 62 62
0.125 48 52 56 56 58 60 60 62 60 60 60 60
0.25 46 52 54 56 58 60 60 54 60 60 60 60
0.5 46 52 54 56 58 60 60 60 60 60 60 60
0.625 46 52 54 58 58 60 62 62 60 60 60 60
0.75 46 50 54 56 58 60 62 62 62 62 60 62
0.875 44 50 56 58 60 62 62 62 62 62 62 60
1 44 52 56 62 62 64 64 64 62 62 62 64
uncut VvDxr 2mM 
NADPH 2mM Mn2+
uncut VvDxr 2mM 
NADPH 2mM Mg2+
32 
 
 
 
Figure 2.12 Thermal stability: VvDxr with ligand screens.  VvDxr was tested with 
numerous ligands to identify small molecular compounds able to improve the 
protein’s thermal stability.   
  
0 30 30 30 54 48 30 30 30 52 48 30 30
0.125 30 30 30 30 30 30 42 46 30 30 30 48 uncut VvDxr DSF L2
0.25 52 30 46 44 30 48 46 30 30 30 46 48
0.5 46 30 30 56 30 46 48 30 30 30 30 30
0.625 50 46 44 30 30 30 46 30 30 44 30 30
0.75 48 46 30 30 44 48 30 30 30 54 30 46
0.875 50 30 30 30 30 44 30 30 30 30 30 46
1 30 30 48 50 46 50 48 48 30 48 30 48
0 44 44 44 46 30 46 48 44 44 30 46 30
0.125 30 30 30 30 44 44 30 46 44 44 58 30 uncut VvDxr DSF L3
0.25 46 30 44 30 30 44 46 46 44 48 40 48
0.5 46 50 32 46 46 46 50 46 56 44 30 62
0.625 50 54 46 52 46 44 46 50 48 30 44 30
0.75 30 30 46 30 48 52 46 44 44 50 62 46
0.875 58 46 46 46 30 48 46 46 56 46 46 30
1 52 30 56 46 44 46 48 46 44 48 60 48
0 46 30 30 30 30 58 30 32 30 30 30 30
0.125 44 46 30 30 50 30 30 30 30 46 30 30 uncut VvDxr DSF L4
0.25 30 30 30 30 30 46 46 30 46 46 48 46
0.5 46 30 30 48 30 46 30 30 30 30 46 30
0.625 46 48 30 30 48 30 30 46 32 44 30 46
0.75 30 30 30 48 46 30 30 40 30 44 30 30
0.875 44 44 46 32 46 48 30 44 30 30 32 30
1 30 30 48 40 48 48 30 30 44 44 30 44
NaCl (M)
NaCl (M)
NaCl (M)
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Figure 2.13 Structure of ligands promoting thermal stability of VvDxr. These 
ligands were identified using DSF ligand screens 
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Figure 2.14. Graph of small molecules promoting thermal stability.  This chart 
gives the melting temperature of VvDxr after being in the presence of the ligands 
named.   
  
50
52
54
56
58
60
62
64
M
EL
TI
N
G
 T
EM
P
ER
A
TU
R
E 
ºC
LIGAND NAME
Ligands Promoting Stability
35 
 
 
 
Figure 2.15. VvDxr in complex with Arginine.  The blue structure is VvDxr in 
complex with arginine, and VvDxr in complex with Mn2i is orange+.  Ligands are 
shown in green. By superposing the structures, manganese is located in the active 
site of the protein, while the arginine is not near the active site.   
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Figure 2.16. ITC with NADPH and Manganese.  The contents of the injector tell 
us how much ligand is used, and the contents of the sample cell give the 
concentration of the protein  
  
Injector 
1mM NADPH 
Sample cell 
0.05 mM VvDxr 
10 mM Tris  
50 mM NaCl 
2 mM Mn
2+
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Figure 2.17. ITC with 2,6 PDC and Magnesium.  The isotherm indicates there is 
protein-ligand binding.  
 
Injector 
1 mM 2,6 PDC 
Sample 
0.05 mM VvDxr 
10 mM Tris 
50 mM NaCl 
2 mM Mg
2+
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Chapter 3 
Materials and Methods 
BACTERIAL TRANSFORMATION 
Recombinant VvDxr was ordered from DNA 2.0 (Mento Park, CA) in 
expression vector pJexpress411 with a cleavable, N-terminal polyhistidine tag 
(MHHHHHHSSGVDLGTENLYFQS↓GSG).  This plasmid was transformed into E. 
coli strain BL21(DE3) and then grown overnight on Luria-Bertani (LB) agar plates 
supplemented with kanamycin.  Colonies from the overnight growth were picked 
and grown.  The GeneJet plasmid miniprep kit (Thermo Scientific, Wilmington, DE) 
was used to extract DNA from the culture. The concentration of the DNA was found 
using a NanoDrop UV/Vis (Thermo Scientific, Wilmington, DE) at an absorbance 
of 260 nm before being taken to the Engencore facility at the University of South 
Carolina for sequencing.  
OVEREXPRESSION AND PURIFICATION OF VVDXR 
Cultures were grown to an OD600 of 0.8 then induced with 400 µM Isopropyl 
β-D-1-thiogalactopyranoside (IPTG) and grown overnight at 16°C.  Culture media 
were centrifuged to pellet cells.  Cells were re-suspended in 30 mL of lysis buffer 
(50 mM Tris, 500 mM NaCl, 10 mM imidazole, 2% glycerol, and 20 mM 2-
mercaptoethanol) and lysed by sonication.  The homogenate was centrifuged, and 
the half of the resulting supernatant was loaded onto Ni-NTA agarose (Thermo 
Scientific, Wilmington, DE) media equilibrated in wash buffer (50 mM Tris, 500 mM 
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NaCl, 30 mM imidazole, 2% glycerol, and 20 mM 2-mercaptoethanol).  The column 
was washed with 10 column volumes of wash buffer before the remaining protein-
containing supernatant was added to the column.  The column was washed again 
with 10 column volumes of wash buffer.  The protein was then eluted from the 
column using ‘elution buffer’ (50 mM Tris, 500 mM NaCl, 250 mM imidazole, 2% 
glycerol, and 20 mM 2-mercaptoethanol).  Fractions were collected and protein-
containing fractions were identified by SDS-PAGE.  Those fractions containing 
protein were pooled and dialyzed in (10 mM Tris, pH 7.4, 150 mM NaCl, 5 mM 2-
mercaptoethanol) overnight.  Protein was concentrated using an Amicon Ultra 
concentrator (Millipore) with a 10, 000 Da molecular mass cutoff and purified on a 
Superdex 200 column attached to an ÄKTA Pure FPLC system (GE Healthcare).  
A solution composed of 10 mM Tris-HCl and 150 mM NaCl at pH 7.4 was used for 
gel filtration of VvDxr.  After gel filtration, fractions containing protein were pooled 
and concentrated to about 9 mg/mL.  Protein concentration was determined using 
the Bradford method [21].  His-tag cleavage was accomplished first by diluting 
uncut VvDxr to 1.5 mg/mL with dialysis buffer.  TEV protease was added to the 
dilute protein-to-protease-to-protein ratio of 1:100 (w/w), then dialyzed overnight 
at 4°C.  Following dialysis, VvDxr was purified again on the ÄKTA Pure FPLC 
system (GE Healthcare).  After gel filtration, fractions containing protein were 
pooled and concentrated to 12 mg/mL. 
VVDXR CRYSTALLIZATION 
Crystallization of VvDxr was performed at 298 K.  All initial crystallization 
experiments were performed using the hanging drop vapor diffusion methods 
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utilizing the Qiagen EasyXtal 15 well plates (Hilde, DE).  The initial screening was 
performed on using Wizard Classic I and II screens (Rigaku, Bainbridge Island, 
WA).  The well contained 400 µL of crystallization condition.  The drops were 
formed by mixing 1 µL of protein solution and 1 µL of screen solution.   
After obtaining initial crystals, VvDxr optimization experiments were 
performed using both the hanging and sitting drop vapor diffusion method.  In the 
hanging drop diffusion method, 400 µL of the optimized crystallization screen was 
added to the well.  The drops were once again formed by mixing 1 µL of protein 
solution and 1 µL of the optimized screen solution.   
The initial sitting drop vapor diffusion experiments were performed utilizing 
NeXtal plates (Qiagen, Chatsworth, CA).  60 µL of the Index screen (Hampton 
Research, Aliso Viejo, CA) were added to the corresponding wells.  The drops 
were formed by mixing 1 µL of protein solution and 1 µL of screen solution. 
DIFFERENTIAL SCANNING FLUORIMETRY 
Differential Scanning Fluorimetry (DSF) was used to determine the thermal 
stability of the.  In this experiment, VvDxr is incubated with Sypro-Orange, a 
fluorescent dye which binds to the hydrophobic residues of the denaturing protein 
[22].  As the experiment proceeds, the protein is heated, exposing the hydrophobic 
residues.  Thermal stability is determined based on the temperature at which they 
fluoresce.   
 Protein stability was determined through pH and salinity screening, and by 
using small molecular compounds.  To determine protein stability using pH and 
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salinity, Sypro-Orange (Life Technologies, Grand Island, NY) was diluted 1:1000 
in 1 mL of a 2 mg/mL VvDxr stock.  The ninety-six buffer screen created in our lab 
contained conditions with pH increasing from 4.0 to 9.5 and increasing NaCl 
concentrations from 0.0 to 1.0 mM.  The screen was transferred into their 
respective wells of the BioRad (Hercules, CA) Hardshell 96-well PCR plate along 
with VvDxr to make a 1:1 Sypro-Orange/VvDxr to buffer. The plate was then 
loaded into the BioRad (Hercules, CA) CFX96 real-time PCR machine and heated 
at 2°C increments per minute, starting at 30°C and ending at 90°C.  As the VvDxr 
is heated, Sypro-Orange binds to the hydrophobic ends and fluoresces.  The 
melting temperature of the protein is determined by the temperature at which the 
probe fluoresces.  Dr. Nicholas Mank (unpublished) developed a protocol for 
interpreting protein melting using the derivative results calculated by the CFX96 
software.  VvDxr stability was also tested by the same method previously 
described using small molecular compounds.  The compound screens were 
developed by solubilizing the compounds before putting them in Tris buffer at pH 
7.5.  The result is three hundred and eighty-four conditions divided into four 
separate screens.  Appendix I gives a list of these conditions.   
ISOTHERMAL TITRATION CALORIMETRY 
 Isothermal titration calorimetry was performed to determine if ligand to 
protein to protein binding was occurring and to study the thermodynamics of the 
binding.  Ligands were dissolved in dialysis buffer containing 10 mM Tris, 50 mM 
NaCl, and either 5 mM Magnesium (II) chloride or Manganese (II) chloride.  A VP-
ITC MicroCalorimeter (GE Healthcare) was used at 25 C VvDxr was present in 
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micromolar concentrations and was loaded into the sample cell.  The ligand-buffer 
mixture was loaded into the injector.  The ligand is slowing injected into the sample 
cell containing the protein.  The enthalpy change was measure based on ligand 
binding.  Separate runs were conducted in which the thermodynamics of binding 
of VvDxr individually to NADPH, NADP, and divalent cations were tested.  Data 
was processed by ORIGIN software.  An isotherm was generated after each run, 
and the number of binding sites can be extrapolated from the point of inflection 
which is the dissociation constant [23]. 
DATA COLLECTION AND PROCESSING 
 VvDxr crystals were cryo-protected with well solution and cryo-cooled in 
liquid nitrogen prior to the diffraction experiments prior to being shipped to the 
Advanced Photon Source in Argonne National Laboratory (ANL) in Lemont, IL.  
Initial data was collected on Sector 22 BM of the Southeast Regional Collaborative 
Access Team (SER-CAT).  Data processing was performed using HKL-2000 [24] 
software.  Details for the data-collection statistics are shown in Tables 2 and 3.  
STRUCTURE DETERMINATION AND VALIDATION 
 VvDxr structures were determined using HKL-3000 [24], MOLREP [25] and 
selected programs from CCP4 suite [29].  Molecular replacement was used for 
phasing.  The native structure of VvDxr was solved using the Escherichia coli Dxr 
homolog (PDB code: 1Q0L) as a starting model.  Other structures of VvDxr were 
determined using Fourier synthesis.  HKL-3000 and REFMAC [31] were used to 
refine all structures, followed by validation using COOT [32] and Molprobity [33].  
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All structures were deposited into the Protein Data Bank (PDB) and were given the 
following accession codes: 5KQO (native VvDxr); 5KS1 (His-tag cleaved VvDxr; 
soaked with fosmidomycin and Mn2+); 5KRR (His-tag cleaved; soaked with Mn2+ 
and FR900098); 5KRY (His-tag cleaved with phosphate-free condition); and 5KRV 
(uncleaved; soaked with Arginine).  Tables 4 and 5 provide a summary of the 
model refinement and validation.   
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Appendix A: DSF Ligand Screening Conditions 
Table A.1. DSF ligand screen 2 
(*All solutions also contain 0.05 M Tris (pH 7.5)*)
A1 0.1M Valine 
A2 0.1M Alanine 
A3 0.1M Arginine 
A4 0.1M Malate 
A5 0.1M Sodium Citrate 
A6 0.1M Threonine 
A7 0.1M Glutamine 
A8 0.1M Isoleucine 
A9 0.1M Succinate 
A10 0.1M Sodium Pyruvate 
A11 0.1M Glucose 
A12 0.1M Lysine 
B1 0.1M Asparagine 
B2 0.1M Homoserine 
B3 0.1M Cytosine 
B4 0.1M Glutamate 
B5 0.1M Proline 
B6 0.1M Taurine 
B7 0.1M Nicotinamide 
B8 0.1M Guanine 
B9 0.1M Glycine 
B10 0.1M Serine 
B11 0.1M Methionine 
B12 0.1M 4-methylcatechol 
C1 0.1M Citrate 
C2 0.1M Nicotinamide 
C3 0.01M Magnesium Chloride 
C4 0.1M Leucine 
C5 0.01M Zinc Chloride 
C6 0.01M Iron(III) Chloride 
C7 0.1M Sodium Pyrophosphate 
C8 0.1M Thymine 
C9 0.1M Sucrose 
C10 0.01M Calcium Chloride 
C11 0.1M Spermidine 
C12 0.1M 2,6-Pyridine dicarboxylic 
acid methyl ester 
D1 0.1M Tryptophan 
D2 0.1M Sodium Cholate 
D3 0.1M Sodium Pyrophosphate 
D4 0.01M Manganese(II) 
Chloride 
D5 0.1M 2,6-Pyridine dicarboxylic 
acid ethyl ester 
D6 0.1M Aspartate 
D7 0.1M Adenine 
D8 0.1M Xylitol 
D9 0.01M Cobalt(II) Chloride 
D10 0.1M 2,6-Pyridine dicarboxylic 
acid 
D11 0.1M Phenylalanine 
D12 0.1M Uracil 
E1 0.1M Mercaptosuccinate 
E2 0.1M γ-amino-butyric acid 
E3 0.1M 8-hydroxy-2-quinole 
carboxylic acid 
E4 0.1M Pimelic acid 
E5 0.1M Sodium Benzene 1,3-
disulfonate 
E6 0.1M 6-oxo-pipecolinic acid 
E7 0.1M Kanamycin 
E8 0.1M 5-amino-isophthalic acid 
E9 0.1M Chelidanic acid 
E10 0.1M 2-pyridine sulfonic acid 
E11 0.1M 2-proline 
E12 0.1M Gly-gly 
F1 0.1M 3,3',5,5'-tetracarboxyl 
diphenalmethane 
F2 0.1M 5-nitrofuroic acid 
F3 0.1M 4,5-dibromo-2-furoic 
acid 
F4 0.1M 5-sulfoisophthalic acid 
F5 0.1M Betaine 
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F6 0.1M isocitric acid lactone 
F7 0.1M 3-aminobenzene 
sulfonic acid 
F8 0.1M Chelidonic acid 
F9 0.1M 1,3,5-benzene 
tricarboxylic acid 
F10 0.1M isocitric acid 
F11 0.1M p-coumaric acid 
F12 0.1M 2,5-thiophene 
dicarboxylic acid 
G1 0.1M Phosphoserine 
G2 0.1M Tartaric acid 
G3 0.1M Arabinose 
G4 0.1M Chloramphenicol 
G5 0.1M Naringin 
G6 0.1M Caffeic acid 
G7 0.1M 2,4-pyridine dicarboxylic 
acid 
G8 0.1M 2,3-pyridine dicarboxylic 
acid 
G9 0.1M 3,5-pyridine dicarboxylic 
acid 
G10 0.1M 2,5-pyridine dicarboxylic 
acid 
G11 0.1M Tyrosine 
G12 0.1M Rutin 
H1 0.1M Morin 
H2 0.01M Copper(II) Chloride 
H3 0.1M Maltose 
H4 0.1M AMP 
H5 0.1M Myo-inositol 
H6 0.1M Ascorbic acid 
H7 0.1M Thiamine 
H8 0.1M Pimelic acid 
H9 0.1M 3-aminobenzene 
sulfonic acid 
H10 0.1M Melamine 
H11 0.1M 2,5 FDC 
H12 0.1M Cystine 
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Table A.2: DSF ligand screen 3 
(*All solutions also contain 0.1 M Tris (pH 7.5)*) 
A1 30% Methanol 
A2 30% Ethanol 
A3 30% DMSO 
A4 40% Acetone 
A5 30% Glycerol 
A6 30% Ethylene Glycol 
A7 0.1M Bromosuccinic acid 
A8 0.1M Cytidine 
A9 0.1M Cytidine in 100% 
Ethanol 
A10 0.1M Sodium Deoxycholate 
A11 0.1M Sodium Chloride 
A12 0.1M Trimesic acid 
B1 0.1M Histidine HCl 
B2 0.1M 1,4-butanediol 
B3 0.1M Neopentyl Alcohol 
B4 0.1M Cadmium Chloride 
B5 0.1M Malonic acid 
B6 0.1M 3,4-dihydroxybenzoic 
acid 
B7 0.1M CHES 
B8 0.1M MOPS 
B9 0.1M L-norvaline 
B10 0.1M 1,6-hexanediol 
B11 0.1M Lanthanum Chloride 
Heptahydrate 
B12 0.1M Vanillin 
C1 0.1M Kanamycin Sulfate 
C2 0.1M N,N-dimethylglycine 
C3 0.1M Salicylic acid 
C4 0.1M 3-hydroxy-2-naphthoic 
acid 
C5 0.1M 
Tris(hydroxymethyl)aminomethane 
C6 0.1M CAPS 
C7 0.1M Ethylene Glycol 
C8 0.1M Chloroquine 
C9 0.1M Potassium Thiocyanate 
C10 0.1M Fast Garnet GBC Salt 
C11 0.1M N,N-
dimethyldecylamine-N-oxide 
C12 0.1M 1,4-butanediphosphonic 
acid 
D1 0.1M Lithium Acetate 
D2 0.1M Magnesium Nitrate 
D3 0.1M Fast Violet B Salt 
D4 0.1M β-NAD 
D5 0.1M α-lactose monohydrate 
D6 0.1M Guanidine Thiocyanate 
D7 0.1M Sodium Bisulfate 
D8 0.1M BOC-L-serine 
D9 0.1M Glutathione (reduced) 
D10 0.1M PIPES 
D11 0.1M Sodium Bicarbonate 
D12 0.1M Thiourea 
E1 0.1M α-naphthyl acid 
phosphate 
E2 0.1M Streptomycin Sulfate 
E3 0.1M Hexamine Cobalt(III) 
Chloride 
E4 0.1M Magnesium Sulfate 
E5 0.1M Lithium Sulfate 
E6 0.1M 4-dimethylaminopyridine 
E7 0.1M S-(-)-2-bromopropionic 
acid 
E8 0.1M O-phospho-DL-serine 
E9 0.1M Nickelous Acetate 
E10 0.1M Tetraamine Copper(II) 
Sulfate 
E11 0.1M Potassium 
Tetrachloroplatinate 
E12 0.1M Ammonium Cerium(IV) 
Nitrate 
F1 0.1M Chromium Acetate 
F2 0.1M Trifluoroacetic acid 
Silver Salt 
F3 0.1M Nicotinic acid 
F4 0.1M Trimethyl Lead Acetate 
F5 0.1M Propylenediphosphonic 
acid 
F6 0.1M Nickel Sulfate 
F7 0.1M Tetraethylpropylene-1,3-
diphosphonic acid 
F8 0.1M 1,6-hexane bis-
phosphonic acid 
F9 0.1M Cesium Fluoride 
F10 0.1M Strontium Nitrate 
F11 0.1M Cobaltous Sulfate 
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F12 0.1M Glutathione 
G1 0.1M Cerous Chloride 
G2 0.1M Sodium Molybdate(III) 
dehydrate 
G3 0.1M Thallium(I) Nitrate 
G4 0.1M Cesium Chloride 
G5 0.1M Iodoacetamide 
G6 0.1M Phosphonoacetic acid 
G7 0.1M 2,6-
naphthalenedisulfonic acid disodium 
salt 
G8 0.1M Propionic acid 
G9 0.1M Calcium Acetate 
G10 0.1M 1,1,3,3-tetramethylurea 
G11 0.1M Adonitol 
G12 0.1M Nicotinamide 
H1 0.1M GMP 
H2 0.1M Cacodylic acid 
H3 0.1M Calcium Formate 
H4 0.1M Lithium Citrate 
H5 0.1M Imidazole 
H6 0.1M Lithium Chloride 
H7 30% Dextrose 
H8 0.1M Sodium Sulfate 
H9 0.1M Thymidine 
H10 0.1M Potassium Hydrogen 
Phthalate 
H11 0.1M Ferrous Sulfate 
H12 0.1M 
Hydroxylaminohydrochloride 
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Table A.3: DSF ligand screen 4  
 (*All solutions also contain 0.1 M Tris (pH 7.5)*)
A1 0.1M ADA (N-2-acetamide-2-
iminodiacetic acid) 
A2 0.1M trans-4,5-dihydroxy-1,2-
dithiane 
A3 0.1M 1-naphthalene acetic 
acid 
A4 0.1M β-alanine 
A5 0.1M Potassium Chloride 
A6 0.1M Cerium(III) Chloride 
Heptahydrate 
A7 0.1M Lithium Fluoride 
A8 0.1M 5,5'-dithiobis(2-
nitrobenzoic acid) 
A9 0.1M 1,2,4,5-
benzenetetracarboxylic acid 
A10 0.1M Cyclohexylsuccinic acid 
A11 0.1M 6-(methoxycarbonyl) 
picolinic acid 
A12 0.1M CHAPS 
B1 0.1M trans-cinnamic acid 
B2 0.1M Sulfonic acid 
B3 0.1M Sodium 3-sulfobenzoate 
B4 0.1M 8-anilino-1-naphthalene 
sulfonic acid 
B5 0.1M N-bromosuccinimide 
B6 0.1M Terephthalic acid 
B7 0.1M Chlorosuccinic acid 
B8 0.1M Guanidine HCl 
B9 2% Triton-X114 
B10 0.1M L-serine 
B11 0.1M Dextrose Anhydrous 
B12 0.1M Sodium Tartrate 
Dihydrate 
C1 0.1M Sodium Acetate 
Trihydrate 
C2 0.1M PEG 400 
C3 10% Poly(vinyl Alcohol) 
C4 0.1M 1,2-dihydroxybenzene 
C5 0.1M Sodium Malonate 
Dibasic Monohydrate 
C6 0.1M 5-aminovaleric acid 
 
C7 0.05M PEG 8000 
C8 0.1M PEG 200 
C9 0.1M NDSB-221 
C10 0.1M NDSB-201 
C11 0.1M 2,2-dimethylsuccinic 
acid 
C12 0.05M PEG 6000 
D1 0.1M PEG 4000 
D2 0.1M NDSB-256 
D3 0.1M Glycerol 
D4 0.1M MES Free Acid 
Monohydrate 
D5 0.1M PEG 2000 MME 
D6 0.1M PEG 5000 MME 
D7 0.1M NDSB-195 
D8 0.1M Phthalic acid 
D9 0.1M 2-methyl-2,4-
pentanediol 
D10 0.1M PEG 3350 
D11 0.1M PEG 1000 
D12 0.1M 2-hydroxy-2-(2-
isopropoxy-2-oxoethyl) succinic acid 
E1 0.1M 6-(ethoxylcarbonyl) 
Picolinic acid 
E2 0.1M EDTA 
E3 0.1M Potassium Sulfate 
E4 0.1M Sodium Carbonate 
E5 0.06M N-bromosuccinic acid 
in 40% Acetone 
E6 0.07M Thymol in 30% Ethanol 
E7 0.07M 2-adamantanone in 
30% Methanol 
E8 0.07M N-bromosuccinic acid 
in 30% DMSO 
E9 0.01M 2,2'-azino-bis(3-
ethylbenzothiazoline-6-sulfonic acid) 
E10 0.07M Sodium Tetraborate in 
30% Ethylene Glycol 
E11 0.1M Mellitic acid 
E12 0.1M methyl-6-hydroxymethyl-
2-carboxylate pyridine 
F1 0.07M Decanoic acid in 30% 
Ethanol 
F2 0.01M Tetrasodium 
Pyrophosphate 
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F3 0.07M Thymine in 30% 
Methanol 
F4 0.01M Calcium Gluconate 
F5 0.01M D-2-phosphoglyceric 
acid 
F6 0.07M 
Hexadecyltrimethylammonium 
bromide in 30% Ethanol 
F7 0.07M 1,3-dicyclohexyl-
carbodiimide in 30% Ethanol 
F8 0.01M Asparagine 
F9 0.01M Calcium Sulfate 
F10 0.07M 2,4-dibromophenol in 
30% Ethanol 
F11 0.01M Adenine 
F12 0.07M 3-amino-4-
hydroxybenzoic acid in 30% Ethanol 
G1 0.06M 3-amino-4-
hydroxybenzoic acid in 40% Acetone 
G2 0.01M Phenylurea 
G3 0.06M Chloramphenicol in 
40% Acetone 
G4 0.07M Thymine in 30% 
DMSO 
G5 0.06M 3-indoleacetic acid in 
40% Acetone 
G6 0.07M Melamine in 30% 
Glycerol 
G7 0.07M 5-iodosalicylic acid in 
30% Ethanol 
G8 0.07M 4-aminobiphenyl in 
30% DMSO 
G9 0.01M Magnesium Citrate 
G10 0.07M Caffeine in 30% 
Ethanol 
G11 0.07M Quinine HCl in 30% 
Ethanol 
G12 0.07M Rhodanine in 30% 
Ethanol 
H1 0.1M (2R,6S)-2,6-
piperdinedicarboxylate 
H2 0.1M 8-aminooctanoic acid 
H3 0.1M O-phospho-L-serine 
H4 0.1M Diphenylamino-4-
sulfonic acid 
H5 0.1M Phytic acid 
H6 0.1M TCEP HCl 
H7 0.01M Samarium Sulfate 
H8 0.01M Dibutylthiourea 
H9 0.07M 2,6-dibromophenol in 
30% Ethanol 
H10 0.07M Kinetin in 30% DMSO 
H11 0.07M 1-phenyl-2-thiourea in 
30% Ethanol 
H12 0.01M Thallium Chloride 
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Appendix B: Optimized Index Conditions 
Table B.1: Optimized Index condition 
Index C10: 1.0 M Succinic Acid pH 7.0, 0.1 M HEPES pH 7.0, 1 % w/v 
PEG 2000   
              
0.5 M 
Succinic 
acid, 1 
% PEG 
2000 
0.8 M 
Succinic 
acid, 1 % 
PEG 2000 
0.9 M 
Succinic 
acid, 1 % 
PEG 2000 
1.0 M 
Succinic 
acid, 1 % 
PEG 2000 
1.1 M 
Succinic 
acid, 1 % 
PEG 2000 
1.2 M 
Succinic 
acid, 1 % 
PEG 2000 
PH = 7, HEPES 
= 0.1 M, different 
PEG and 
Succinic acid 
concentrations 
0.5 M 
Succinic 
acid, 2 
% PEG 
2000 
0.8 M 
Succinic 
acid, 2 % 
PEG 2000 
0.9 M 
Succinic 
acid, 2 % 
PEG 2000 
1.0 M 
Succinic 
acid, 2 % 
PEG 2000 
1.1 M 
Succinic 
acid, 2 % 
PEG 2000 
1.2 M 
Succinic 
acid, 2 % 
PEG 2000 
0.5 M 
Succinic 
acid, 4 
% PEG 
2000 
0.8 M 
Succinic 
acid, 4 % 
PEG 2000 
0.9 M 
Succinic 
acid, 4 % 
PEG 2000 
1.0 M 
Succinic 
acid, 4 % 
PEG 2000 
1.1 M 
Succinic 
acid, 4 % 
PEG 2000 
1.2 M 
Succinic 
acid,  
0.5 M 
Succinic 
acid, 3% 
PEG 
2000 
0.8 M 
Succinic 
acid,  3% 
PEG 2000 
0.9 M 
Succinic 
acid, 3 % 
PEG 2000 
1.0 M 
Succinic 
acid, 3 % 
PEG 2000 
1.1 M 
Succinic 
acid, 3 % 
PEG 2000 
1.2 M 
Succinic 
acid,   
              
PH 7.6, 
PEG 1 
% 
PH 7.6, 
PEG 2% 
PH 7.6 
PEG 3% 
PH 7.6 
PEG 4% 
PH 7.6  
PEG 5%   
Same Succinic 
acid 
concentration= 1 
M, HEPES = 0.1 
M, different PEG 
concentration 
and pH  
PH 7.2  
PEG 1 
% 
PH 7.2 
PEG 2% 
PH 7.2  
PEG 3% 
PH 7.2  
PEG 4% 
PH 7.2  
PEG 5%   
PH 6.8  
PEG 1 
% 
PH 6.8  
PEG 2% 
PH 6.8  
PEG 3% 
PH 6.8  
PEG 4% 
PH 6.8  
PEG 5%   
PH 6.4  
PEG 1 
% 
PH 6.4   
PEG 2% 
PH 6.4  
PEG 3% 
PH 6.4  
PEG 4% 
PH 6.4  
PEG 5%   
 
 
 
